Recruiting

Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery

ClinicalTrials.gov IDNCT06297265

PhaseNA

Enrollment50

SponsorUniversity of Southern California

Age18 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Localized Breast Carcinoma

About this study

This phase II trial evaluates manual lymphatic drainage breast massage for reducing treatment-related side effects in women undergoing radiation therapy after breast conserving surgery for breast cancer that has not spread to other parts of the body (localized). Breast conserving surgery can be an effective treatment option for early stage breast cancer, but it can also be associated with side effects including fluid collection in tissues/swelling (lymphedema), pain, reduced quality of life, and poorer body image. Manual lymphatic drainage is a gentle massage technique used to reduce swelling. It may be a safe and effective way to reduce treatment-related side effects in women receiving radiation therapy after surgery for localized breast cancer.

Interventions

Other: Lymphedema Management — Undergo MLD breast massage
Other: Questionnaire Administration — Ancillary studies
Radiation: Adjuvant breast radiation therapy — Using standard 3D conformal or intensity modulated techniques, patients will receive standard fractionation or moderate hypofractionation radiation therapy. The radiation treatment will last for 3 to 6 weeks, with the length of treatment depending on patient's specific clinical situation.

Primary outcomes

Rate of compliance of MLD breast massage sessions (Up to 1 month after completion of radiation)

Eligibility information

Inclusion Criteria: * Female with native breasts and localized breast cancer who are status post-lumpectomy surgery, will receive whole breast radiation therapy with/without nodal irradiation, with standard fractionation or moderate hypofractionation * Age \>= 18 years * Ability to understand and the willingness to sign a written informed consent in English or Spanish Exclusion Criteria: * Underlying diagnosis of chronic inflammatory illness or collagen vascular disorder, e.g. scleroderma, lupus, rheumatoid arthritis, fibromyalgia as these conditions may significantly affect the likelihood and magnitude of radiation related toxicity * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Inability to provide written informed consent in English or Spanish * Patients receiving ultra-hypofractionation, and/or partial breast or chest wall radiation therapy are excluded

Study locations

USC / Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.